Autoantibodies to Tumor-Associated Antigens as Cancer Biomarkers

Belousov, Pavel V.; Kuprash, Dmitry V.; Недоспасов, С А; Shebzukhov, Yuriy V.

doi:10.2174/156652410790963259

Cited by 11 publications

(9 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor associated antigens (TAAs) which are highly expressed in the process of tumorigenesis and progression, can induce immune response [14]. Compared with TAAs, TAAbs have amplification effects and are easily detectable, thus TAAbs can be used as tumor markers [15]. In recent years, TAAbs have been used in LC auxiliary diagnosis; however, the conclusion of their diagnostic efficacy was partially consistent [9,16].…”

Section: Discussionmentioning

confidence: 99%

Seven Tumor-Associated Autoantibodies as a Eerum Biomarker for Primary Screening of Non-Small Cell Lung Cancer

Chen

Lü

Chen

2021

Preprint

View full text Add to dashboard Cite

Objective: Tumor-associated autoantibodies (TAAbs) are produced by the organism in response to peptides at the surface of tumor cells or proteins released by tumors. The purpose of this study is to analyze the expression of TAAbs in different pathological stages and determine their diagnostic value in early non-small cell lung cancer (NSCLC). Methods: We retrospectively analyzed the expression of 7-TAAbs in 216 newly diagnosed NSCLC patients, 202 patients with lung benign diseases and 137 healthy cases. The expression of a panel of 7-TAAbs, including p53, GAGE7, PGP9.5, CAGE, MAGE A1, SOX2, GBU4-5, was measured by ELISA. Results: The serum levels of p53, GAGE7, PGP9.5, CAGE, MAGE A1, SOX2 and GBU4-5 were not statistically significant (P>0.05) in NSCLC, benign and healthy groups. The area under the curve (AUC) of 7-TAAbs were all lower than 0.70. The sensitivity of combined detection was the highest (26.39%), while the specificity was the lowest (88.62%). PGP9.5, SOX2, GAGE7, MAGE A1 and combined detection were significantly different among the three groups (P < 0.05). PGP9.5, GAGE7, MAGE A1 and combined detection were significantly different between the NSCLC and benign groups (P < 0.05). PGP9.5, SOX2, GAGE7 and combined detection were significantly different between the NSCLC and healthy groups (P < 0.05). The positive rate of the combined detection of 7-TAAbs was 44.44% in NSCLC stage IV, while that in the other three stages was less than 30.00%. Conclusions: The sensitivity of 7-TAAbs in early NSCLC was not high, so it cannot be used alone as a screening method for NSCLC. In view of the differences of positive rate between the NSCLC and non- NSCLC groups, 7-TAAbs can be used as a supplementary mean of NSCLC screening.

show abstract

Section: Discussionmentioning

confidence: 99%

Seven Tumor-Associated Autoantibodies as a Eerum Biomarker for Primary Screening of Non-Small Cell Lung Cancer

Chen

Lü

Chen

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Due to the efficient biological amplification of circulating autoantibodies, they may be present at high concentrations in blood [18]. In addition, they are not subjected to proteolysis like other polypeptides [19], autoantibodies are largely stable in serum for a relatively long period of time (T1/2 of between 7 and 30 days, depending on the subclass of immunoglobulin).…”

Section: Discussionmentioning

confidence: 99%

Potential application of non-small cell lung cancer-associated autoantibodies to early cancer diagnosis

Yao

Fan

et al. 2012

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

“…To date, many types of antibodies have been correlated with carcinoma [11]. ACA has been found in breast carcinoma, which targets centrosome antigens.…”

Section: Introductionmentioning

confidence: 99%

MAD2 Combined with Mitotic Spindle Apparatus (MSA) and Anticentromere Antibody (ACA) for Diagnosis of Small Cell Lung Cancer (SCLC)

Tan

Chen

et al. 2018

Med Sci Monit

View full text Add to dashboard Cite

BackgroundMAD2 is the gene controlling mitosis. Many studies have assessed MAD2 in various types of carcinoma. Antinuclear mitotic spindle apparatus antibody (MSA) and anticentromere antibody (ACA) are related mitotic antibodies, playing roles in autoimmune diseases and carcinomas, but the expression of MAD2, MSA, and ACA in SCLC is unclear.Material/MethodsWe enrolled 70 SCLC patients, 72 non-small cell lung cancer (NSCLC) patients, and 65 pulmonary nodule (PN) patients. MAD2 expression was measured through agarose electrophoresis and qt-PCR. Antinuclear mitotic spindle apparatus antibody (MSA) and anticentromere antibody (ACA) were detected by indirect immunofluorescence (IIF).ResultsMAD2 was found both in SCLC and NSCLC. Interestingly, there was a significant difference found between SCLC and NSCLC using qt-PCR (P<0.05). The area under the ROC curve of MAD2 expression was 0.799, with medium diagnostic value. MAD2 expression was related to age, lymphatic metastasis, and survival time, but not with sex. The positivity for MSA and ACA by IIF assay were 37.20% and 34.00%, respectively, in the SCLC group, which were higher than in the NSCLC and pulmonary nodule groups (P<0.05). The kappa values of MSA and ACA with MAD2 expression were 0.73 and 0.65, respectively, with moderate consistency. Combining MAD2 with MSA and ACA enhanced the sensitivity and specificity for diagnosing SCLC.ConclusionsMAD2 expression was found to be involved in carcinogenesis and prognosis of SCLC. The combination of MAD2 with MSA and ACA is useful for early diagnosis and shows promise in treatment of SCLC.

show abstract

Autoantibodies to Tumor-Associated Antigens as Cancer Biomarkers

Cited by 11 publications

References 76 publications

Seven Tumor-Associated Autoantibodies as a Eerum Biomarker for Primary Screening of Non-Small Cell Lung Cancer

Seven Tumor-Associated Autoantibodies as a Eerum Biomarker for Primary Screening of Non-Small Cell Lung Cancer

Potential application of non-small cell lung cancer-associated autoantibodies to early cancer diagnosis

MAD2 Combined with Mitotic Spindle Apparatus (MSA) and Anticentromere Antibody (ACA) for Diagnosis of Small Cell Lung Cancer (SCLC)

Contact Info

Product

Resources

About